Bitter Melon
Momordica charantia
TL;DR
Bitter melon has a strong mechanistic story for blood glucose and a disappointing clinical record. Randomised trials at 2,000 mg/day show small or absent HbA1c changes, and direct comparisons against metformin have consistently favoured the drug.
Ideal For
- Prediabetes, as a minor dietary adjunct
- People already using bitter melon as a food
- Adjunct alongside — never instead of — prescribed therapy
Avoid If
- Pregnancy
- G6PD deficiency
- Using it as a substitute for prescribed diabetes medication
- Children, where hypoglycaemic reactions to seeds are reported
Frequently Asked Questions
Overview
Bitter melon is a useful reminder that a compelling mechanism does not guarantee a clinical effect. The fruit contains polypeptide-p, sometimes called plant insulin, along with charantin and cucurbitane triterpenoids, all of which lower glucose convincingly in cell culture and rodent models. Human trials tell a different story. A Cochrane review found insufficient evidence to recommend it for type 2 diabetes, and a randomised four-arm trial comparing bitter melon at doses up to 2,000 mg/day against metformin found a significantly smaller reduction in fructosamine with the botanical. Some smaller trials do report modest fasting glucose reductions, and there may be a role as a minor adjunct in prediabetes, but the honest position is that anyone using bitter melon in place of established therapy is trading a proven treatment for a marginal one. Safety adds a further constraint: the seeds contain vicine, which can trigger haemolysis in G6PD deficiency, and the fruit has documented abortifacient activity.
How It Works
- Polypeptide-p has insulin-like activity in animal models
- Charantin activates AMPK and GLUT4 translocation
- Inhibits intestinal glucose absorption
- Human effect sizes fall far short of the preclinical signal
Quick Facts
- Cochrane found insufficient evidence in type 2 diabetes
- Performed worse than metformin in head-to-head trial
- Seeds contain vicine — dangerous in G6PD deficiency
- Documented abortifacient activity
Benefits & Outcomes
No linked outcomes yet. Research is ongoing.
Supporting Research11 studies
Momordica charantia for type 2 diabetes mellitus
Ooi CP, Yassin Z, Hamid TA
There is insufficient evidence to recommend Momordica charantia for type 2 diabetes; trials showed no statistically significant difference in glycaemic control versus placebo or metformin.
The Effects of Bitter Melon (Momordica charantia) on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Amini MR, Rasaei N, Jalalzadeh M +2 more
Bitter melon consumption resulted in a significant decrease in plasma concentrations of TC (WMD; -9.71 mg/dL) and TG (WMD; -10.24 mg/dL)
The metabolic effect of Momordica charantia cannot be determined based on the available clinical evidence: a systematic review and meta-analysis of randomized clinical trials
Kalman DS, et al.
Pooled analysis found no reliable effect of M. charantia on fasting glucose, HbA1c or lipid parameters, with very low certainty of evidence.
The effects of bitter melon (Momordica charantia) on anthropometric indices in adults: A systematic review and meta-analysis of randomized controlled trials
Zou Y, Zou W, Jahangir M +1 more
There was no significant impact of bitter melon supplementation on BW, BMI, WC, and PBF.
Effects of Momordica charantia L. supplementation on glycemic control and lipid profile in type 2 diabetes mellitus patients: A systematic review and meta-analysis of randomized controlled trials
Nagarani G, et al.
Pooled results suggested a small reduction in fasting blood glucose with M. charantia but no significant change in HbA1c or lipid profile, with GRADE certainty rated low.
Momordica charantia for type 2 diabetes mellitus: hypoglycemic efficacy and safety in patients with type 2 diabetes mellitus
Kim SK, Jung J, Jung JH +2 more
After treatment with bitter melon extract for 12 weeks, the HbA1c levels of the bitter melon and placebo groups remained unchanged; however, the average fasting glucose level of the bitter melon group decreased (p = 0.014).
Bitter gourd (Momordica charantia L.) supplementation for twelve weeks improves biomarkers of glucose homeostasis in a prediabetic population
Mes JJ, van den Belt M, van der Haar S +2 more
In Study 2, we observed significant reductions of FPG (p = 0.014)
Investigation of the Influence of a Bitter Melon Product on Indicators of Cardiometabolic Health in Adults with Prediabetes
Guarneiri LL, Wilcox ML, Kuan CM +1 more
The bitter melon extract may help maintain a healthy level of glucose in adults with prediabetes.
Momordica charantia Administration Improves Insulin Secretion in Type 2 Diabetes Mellitus
Cortez-Navarrete M, Martínez-Abundis E, Pérez-Rubio KG +2 more
A significant increase in insulin AUC (56,562 ± 36,078 vs. 65,256 ± 42,720 pmol/L/min, P = .043)
Effect of Momordica charantia Administration on Anthropometric Measures and Metabolic Profile in Patients with Obesity: A Pilot Clinical Trial
Cortez-Navarrete M, Méndez-Del Villar M, Martínez-Abundis E +2 more
no significant reductions in BW, BMI, WC, and body fat percentage were observed after MC administration; however, MC significantly decreased TG and VLDL levels
The effects of Momordica charantia (bitter melon) supplementation in patients with primary knee osteoarthritis: A single-blinded, randomized controlled trial
Soo May L, Sanip Z, Ahmed Shokri A +2 more
Momordica charantia supplementation offers a safe alternative to reducing pain and improving symptoms among the primary knee osteoarthritis patients while reducing the need for analgesia consumption.
Safety Information
Potential Side Effects
Gastrointestinal upset, abdominal pain and diarrhoea are common at higher doses. Headache and hypoglycaemia can occur when combined with glucose-lowering drugs.
Contraindications
Contraindicated in pregnancy owing to documented abortifacient activity. Avoid in G6PD deficiency because seed vicine can precipitate haemolysis.
Drug Interactions
- Insulin and sulfonylureas — additive hypoglycaemia risk
- Metformin — additive effect but no benefit demonstrated over metformin alone
- Antidiabetic agents generally — monitor glucose when starting
Pregnancy & Breastfeeding
Pregnancy: unsafe
Breastfeeding: likely_unsafe
Dosage Guidelines
Dosage Used in Studies
500-2000 mg
Best Time to Take
Divided doses before meals
Best Form
Standardised fruit extract; seed-free preparations preferred
Bioavailability
Poor for the peptide fraction, which is likely degraded in the gut; triterpenoid absorption is modest.
Forms Compared
Standardised fruit extract
Fresh juice
Whole fruit as food
Food & Timing
Take before meals to target post-prandial glucose absorption.
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.